Scientific intelligence record
Experience 2.0
PTHrP analog
Abaloparatide is a synthetic 34-residue analog of human parathyroid hormone-related protein, PTHrP(1–34), designed to activate the parathyroid hormone type 1 receptor. Intermittent subcutaneous exposure produces an osteoanabolic response by stimulating osteoblast activity and increasing bone formation. The molecule contains an α-aminoisobutyric-acid substitution and is distinct from endogenous PTHrP and from teriparatide. Regulatory authorization is product- and jurisdiction-specific: the FDA-approved TYMLOS label covers defined high-fracture-risk postmenopausal women and men, while the EMA-authorized ELADYNOS indication is for postmenopausal women at increased fracture risk.
Record status
Traceability partial
Last meaningful update: 9/20/2026
global evidence atlas
This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
454 matching records · ranked 2026-09-18
Page 1 of 19
Europe PMC · 2026 · PMID 41688596 · DOI 10.1007/s43390-026-01307-z
human-observational
Europe PMC · 2026 · PMID 41506099 · DOI 10.1016/j.bioadv.2025.214700
preclinical-animal
OpenAlex · 2026 · Source ID doi:10.1080/26315904.2026.2688294 · DOI 10.1080/26315904.2026.2688294
preclinical-animal
Europe PMC · 2026 · PMID 41798079 · DOI 10.1016/j.jbo.2026.100752
preclinical-animal
Europe PMC · 2026 · PMID 42618812 · DOI 10.1007/s00198-026-08176-2
human-interventional
OpenAlex · 2026 · Source ID doi:10.64918/20.500.12503/33520 · DOI 10.64918/20.500.12503/33520
preclinical-animal
Europe PMC · 2026 · PMID 41714054 · DOI 10.1016/j.job.2025.100708
preclinical-animal
OpenAlex · 2026 · Source ID doi:10.1007/s40619-026-01762-w · DOI 10.1007/s40619-026-01762-w
preclinical-animal
Europe PMC · 2026 · PMID 41579168 · DOI 10.1007/s00210-026-04984-9
preclinical-animal
Europe PMC · 2026 · PMID 42671953 · DOI 10.1159/ajn/ablag003
preclinical-animal
Europe PMC · 2026 · PMID 42577358 · DOI 10.3389/fragi.2026.1886673
preclinical-animal
OpenAlex · 2026 · Source ID doi:10.1530/boneabs.08.p44 · DOI 10.1530/boneabs.08.p44
preclinical-animal
Europe PMC · 2026 · PMID 42351259 · DOI 10.1186/s13256-026-06289-0
human-observational
Europe PMC · 2026 · PMID 42535103 · DOI 10.1155/joos/2813928
human-observational
Europe PMC · 2026 · PMID 41701231 · DOI 10.1007/s00198-026-07864-3
preclinical-animal
Europe PMC · 2026 · PMID 41993988 · DOI 10.3389/fendo.2026.1714141
synthesis
Europe PMC · 2026 · PMID 42181204 · DOI 10.3389/fendo.2026.1836818
synthesis
Europe PMC · 2026 · PMID 42532988 · DOI 10.1038/s41413-026-00555-z
preclinical-animal
Europe PMC · 2026 · PMID 42298929
human-observational
Europe PMC · 2026 · PMID 42494861 · DOI 10.3389/fendo.2026.1886136
synthesis
Europe PMC · 2026 · PMID 41143882 · DOI 10.1007/s00198-025-07668-x
human-observational
Europe PMC · 2026 · PMID 42461643 · DOI 10.1001/jama.2026.11895
preclinical-animal
Europe PMC · 2026 · PMID 42494964 · DOI 10.1177/1759720x261466911
preclinical-animal
Europe PMC · 2026 · PMID 40304326 · DOI 10.2174/0118715303206506250404180458
preclinical-animal
Europe PMC · 2026 · PMID 41854838 · DOI 10.1007/s40266-026-01290-0
human-observational
governance and regulatory context
No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.
Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.
ELADYNOS (abaloparatide) is centrally authorised in the European Union for treatment of osteoporosis in postmenopausal women at increased risk of fracture.
EMA EPAR — Eladynos (EMEA/H/C/005928)TYMLOS (abaloparatide) is FDA-approved for treatment of postmenopausal women with osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy, and to increase bone density in men with osteoporosis at high risk for fracture or with the same treatment-history criteria.
Abaloparatide evidence · ranking key
A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.
Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.
Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.
Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.
Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.
peptide explorer
Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.
Fully specified molecular identity
Complete registered analog identity; viewer geometry is representative only.
Sources: NIH PubChem — Abaloparatide · reviewed 2026-09-17
APA
World Peptide Foundation. (n.d.). Abaloparatide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/abaloparatide
AMA / Vancouver
World Peptide Foundation. Abaloparatide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/abaloparatide
Ranked research corpus
454
Categorized publications with transparent machine-proposed ranking; human appraisal pending.
Featured tiered studies
0
Cornerstone publications with study-level interpretation, limitations, and tier disclosure.
Research domains
6
Clinical and scientific questions synthesized independently across the evidence atlas.
Governed reviewed evidence
25
Database records promoted through the governed publication workflow—not the corpus total.
Corpus generated 2026-09-18. Counts remain separately labeled to prevent automated screening from being represented as completed human review.
Human experience · separate evidence stream
Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.
Observation is valuable human context. It is not evidence of causation, efficacy, or safety.
Public display gate
n ≥ 20 eligible observations
Exact progress remains private before the threshold.
Intelligence snapshot
A compact view of what is represented, what remains unresolved, and how completely the record can be traced.
Ranked research corpus
454
Categorized screening records; proposed rankings remain pending human appraisal.
Featured tiered studies
0
Cornerstone studies with published study-level interpretation and tier disclosure.
Research domains
6
Independent evidence dossiers covering the major research questions.
Governed reviewed evidence
25
Reviewed database records promoted through the governed publication workflow.
Contradictions
0
Conflicting evidence relationships that remain visible.
Research gaps
1
Questions the current record identifies as unresolved.
Connected media
0
Media records explicitly linked to this scientific record.
What we know
The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.
Reconciled domain conclusions
Abaloparatide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.
Inspect the reconciled evidence atlasThis score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The ACTIVE study demonstrated the antifracture efficacy of abaloparatide in postmenopausal women with osteoporosis.
Scientific context
Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.
Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.
Explore further
Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.
Research
Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.
2016 · study · Temporal status not established
JAMA
2017 · study · Temporal status not established
Bone
2017 · study · Temporal status not established
Cureus
2017 · study · Temporal status not established
Drugs
2018 · study · Temporal status not established
The Journal of clinical endocrinology and metabolism
2018 · study · Temporal status not established
The Annals of pharmacotherapy
2019 · study · Temporal status not established
The Journal of clinical endocrinology and metabolism
2019 · study · Temporal status not established
Biochemical pharmacology
2019 · study · Temporal status not established
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
2019 · study · Temporal status not established
Macromolecular bioscience
2020 · study · Temporal status not established
The Journal of clinical endocrinology and metabolism
2021 · study · Temporal status not established
European journal of pharmacology
2022 · study · Temporal status not established
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2023 · study · Temporal status not established
Archives of osteoporosis
2023 · study · Temporal status not established
Journal of bone and mineral metabolism
2023 · study · Temporal status not established
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2023 · study · Temporal status not established
Bone
2023 · study · Temporal status not established
BMJ (Clinical research ed.)
2023 · study · Temporal status not established
Annals of internal medicine
2024 · study · Temporal status not established
The Journal of bone and joint surgery. American volume
2024 · study · Temporal status not established
Clinical therapeutics
2025 · study · Temporal status not established
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2025 · study · Temporal status not established
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2025 · study · Temporal status not established
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2025 · study · Temporal status not established
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
2026 · regulatory · Temporal status not established
European Union (EMA)
2026 · regulatory · Temporal status not established
United States (FDA)
The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.
No institutional claim record is currently represented for this peptide.
Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.
These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.
4 represented evidence records
Years represented: 2022, 2023, 2025
Publishing organizations appearing in records: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
4 represented evidence records
Years represented: 2016, 2018, 2025
Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, JAMA, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, The Journal of clinical endocrinology and metabolism
3 represented evidence records
Years represented: 2016, 2018, 2020
Publishing organizations appearing in records: JAMA, The Journal of clinical endocrinology and metabolism
3 represented evidence records
Years represented: 2016, 2017, 2018
Publishing organizations appearing in records: Bone, JAMA, The Journal of clinical endocrinology and metabolism
Connections
Connections appear only when they are represented by the project’s underlying records.
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
institution
Traceability
The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.
Source publication state
A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.
Reviewer provenance state
“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.
Domain conclusion → Evidence
Connected
Evidence → Source
Connected
Source → Original record
Connected
Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.
Reconciled for 6 domain conclusions and 0 featured studies.
Detailed study-to-domain mappings and original-source paths appear in the Abaloparatide evidence-governance section.
Inspect the ranked source recordsObservational archive
Observational archive data is intentionally separated from published scientific evidence.
Observational boundary
Insufficient eligible observations are available for display under the current filters.
Insufficient eligible observations are currently represented to display aggregated findings for this peptide.
Regulatory context
Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.
European Union (EMA)
Regulator: EMA
As of: 9/9/2026 · Temporal status not established
United States (FDA)
Regulator: FDA
As of: 9/9/2026 · Temporal status not established
FDA Drugs@FDA NDA 208743 and TYMLOS Prescribing Information, revised August 2026
Research + media
Only media explicitly linked through the project’s relationship system appears here.
No scientifically connected media is currently represented for this peptide.
Sources + provenance
Generated: 9/24/2026, 3:25:13 AM
1 FDA structured product label record(s) were identified for this compound name in openFDA. Label presence reflects an approved product exists under that name; it is not a claim about the specific formulation, dose, or use being discussed anywhere else on this page.
No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.
Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.
Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.
This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Additional therapies are needed for prevention of osteoporotic fractures.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
There are a number of effective treatments for osteoporosis but most are in the antiresorptive class of compounds.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Daily subcutaneous injection of 80 μg abaloparatide increased bone mineral density in Japanese patients with osteoporosis at high fracture risk in the ACTIVE-J trial.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Early increases in bone turnover markers (BTMs) in response to anabolic therapy correlate with 18-mo BMD increases in postmenopausal women with osteoporosis; however, this relationship has not been assessed in men.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Low hip bone mineral density (BMD) in patients who undergo total hip arthroplasty (THA) increases the risk of periprosthetic fractures, implant instability, and other complications.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide significantly increased bone mineral density (BMD) in women with postmenopausal osteoporosis and decreased risk of vertebral, nonvertebral, and clinical fractures compared with placebo.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
In women with postmenopausal osteoporosis, we investigated the effects of 24 months of treatment with alendronate (ALN) following 18 months of treatment with abaloparatide (ABL) or placebo (PBO).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The goal of treatment for women at high risk of fracture who have a T-score ≤-2.5 is to mitigate fracture risk by achieving T-scores at least above -2.5.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
This study aimed to determine the efficacy of abaloparatide in increasing bone mineral density (BMD) and its safety in postmenopausal Japanese women with osteoporosis.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Anabolic therapies, recommended for patients at very high fracture risk, are administered subcutaneously (SC).
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide (previously known as BA058) is a synthetic 34-amino acid peptide and novel selective activator of parathyroid hormone receptor 1 (PTHR1) currently under development as a new anabolic agent in the management of osteoporosis.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide (Tymlos™) is a synthetic peptide analogue of human parathyroid hormone-related protein that was developed by Radius Health as an osteoanabolic agent for the treatment of postmenopausal osteoporosis.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Osteoporosis medications have been reported to have beneficial and harmful cardiovascular effects.
To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide and teriparatide are osteoanabolic treatments indicated for postmenopausal women and men with osteoporosis at high risk of fracture.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The aging of the population increases the incidence of postmenopausal osteoporosis, which threatens the health of elderly women.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Osteoporosis, defined by reduced bone mineral density and macro- and micro-architectural degradation, leads to increased fracture risk, particularly in aging populations.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Osteoporosis and osteopenia are associated with increased fracture incidence in postmenopausal women.
The prevalence of osteoporosis is increasing in the United States.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Osteoporosis is a debilitating disease characterized by reduced bone mineral density and an increased risk of fractures.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Abaloparatide is an analog of human parathyroid hormone-related protein (PTHrP) that has recently been approved for the treatment of post-menopausal osteoporosis.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
The efficacy and safety of abaloparatide, a parathyroid hormone-related protein analog for the treatment of osteoporosis in postmenopausal women at high fracture risk, is reviewed.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
To review the efficacy, safety, and economics of abaloparatide in the treatment of postmenopausal osteoporosis.
This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.
Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.
Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.
Methodology: WPF-ESR-1.0
Side-effects from allograft, limited bone stock, and site morbidity from autograft are the major challenges to traditional bone defect treatments.
3 represented evidence records
Years represented: 2016, 2018, 2020
Publishing organizations appearing in records: JAMA, The Journal of clinical endocrinology and metabolism
3 represented evidence records
Years represented: 2022, 2023, 2025
Publishing organizations appearing in records: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
5 represented evidence records
Years represented: 2017, 2024, 2025
Publishing organizations appearing in records: Bone, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, The Journal of bone and joint surgery. American volume
2 represented evidence records
Years represented: 2018, 2020
Publishing organizations appearing in records: The Journal of clinical endocrinology and metabolism
2 represented evidence records
Years represented: 2017, 2025
Publishing organizations appearing in records: Bone, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2 represented evidence records
Years represented: 2022, 2023
Publishing organizations appearing in records: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2 represented evidence records
Years represented: 2022, 2025
Publishing organizations appearing in records: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
2 represented evidence records
Years represented: 2022, 2023
Publishing organizations appearing in records: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research